Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study

Highlights • clarithromycin may be of benefit in lung cancer but controlled data are lacking. • this study was undertaken to inform the feasibility and scale of a phase III trial. • of 125 patients identified over 6 months, none fulfilled the entry criteria. • 36% were ineligible because of an exclu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-02, Vol.104, p.75-78
Hauptverfasser:	Awan, Sarah, Crosby, Vincent, Potter, Vanessa, Hennig, Ivo, Baldwin, David, Ndlovu, Mehluli, Paradine, Sharon, Wilcock, Andrew
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - pharmacology Cachexia Cachexia - drug therapy Cachexia - mortality Carcinoma, Non-Small-Cell Lung - complications Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Clarithromycin Clarithromycin - administration & dosage Clarithromycin - pharmacology Clinical Trials, Phase III as Topic Disease-Free Survival Double-Blind Method Feasibility Studies Female Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - complications Lung Neoplasms - drug therapy Lung Neoplasms - pathology Macrolide antibiotics Macrolides Male Medication Adherence Neoplasm Staging Non-small cell lung cancer Placebos Pulmonary/Respiratory Randomized Controlled Trials as Topic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • clarithromycin may be of benefit in lung cancer but controlled data are lacking. • this study was undertaken to inform the feasibility and scale of a phase III trial. • of 125 patients identified over 6 months, none fulfilled the entry criteria. • 36% were ineligible because of an excluded concurrent drug. • macrolides with fewer drug-drug interactions may be more practical to pursue.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2016.12.010